IDH1 mutations in a Brazilian series of Glioblastoma
نویسندگان
چکیده
Miyuki Uno, Sueli Mieko Oba-Shinjo, Roseli da Silva, Flavio Miura, Carlos Afonso Clara, José Reynaldo Walther de Almeida, Suzana M. F. Malheiros, André Macedo Bianco, Reynaldo Brandt, Guilherme Carvalhal Ribas, Halim Feres, Carlos Dzik, Sérgio Rosemberg, João Norberto Stavale, Manoel Jacobsen Teixeira, Suely K. N. Marie I Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil. II Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil. III Cancer Institute of Sao Paulo, São Paulo, São Paulo, Brazil. IV Barretos Cancer Hospital (Fundação Pio XII), Barretos, São Paulo, Brazil. V Department of Neurology, School of Medicine, Federal University of Sao Paulo, Brazil. VI Department of Pathology, School of Medicine, Federal University of Sao Paulo, Brazil. VII Nove de Julho Hospital, São Paulo, Brazil. VIII Albert Einstein Jewish Hospital, Sao Paulo, Brazil.
منابع مشابه
IDH1 Mutation in Gliomas in Mosul City - Iraq
BACKGROUND IDH1 (isocitrate dehydrogenase 1) mutation might be encounter in the low grade glioma and directs the progression of the tumor to a higher grade. OBJECTIVE To assess the frequency of IDH1 mutations in gliomas and to correlate the IDH1 positivity with the type and grade of tumors, the age and sex of the patients. MATERIAL AND METHODS A retro- and prospective case series study. One...
متن کاملIsocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered to be frequent and highly conserved in secondary glioblastoma multiforme and lower-grade gliomas. Although IDH1 mutations confer a unique genotype that has been associated with a favorable prognosis, the role of the mutated IDH1 enzyme and its metabolites in tumor initiation and maintenance remains unresolved. However, given that ...
متن کاملLong-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
PURPOSE The determinants of long-term survival in glioblastoma have remained largely obscure. Isocitrate dehydrogenase (IDH) 1 or 2 mutations are common in World Health Organization (WHO) grades II and III gliomas, but rare in primary glioblastomas, and associated with longer survival. EXPERIMENTAL DESIGN We compared clinical and molecular characteristics of 69 patients with centrally confirm...
متن کاملIDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
IDH1 encodes isocitrate dehydrogenase 1, which participates in the citric acid cycle and was recently reported to be mutated in 12% of glioblastomas. We assessed IDH1 mutations in 321 gliomas of various histological types and biological behaviors. A total of 130 IDH1 mutations was detected, and all were located at amino acid residue 132. Of these, 91% were G-->A mutations (Arg-->His). IDH1 muta...
متن کاملIDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
PURPOSE To establish the frequency of IDH1 mutations in glioblastomas at a population level, and to assess whether they allow reliable discrimination between primary (de novo) glioblastomas and secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma. EXPERIMENTAL DESIGN We screened glioblastomas from a population-based study for IDH1 mutations and correlated them with...
متن کاملIDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Isocitrate dehydrogenase (IDH) enzymes have recently become a focal point for research aimed at understanding the biology of glioma. IDH1 and IDH2 are mutated in 50%-80% of astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas but are seldom mutated in primary glioblastomas. Gliomas with IDH1/2 mutations always harbor other molecular aberrations, such as TP53 mutation...
متن کامل